Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Capital Leases (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Capital Leases for 6 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Leases fell 4.7% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Dec 2025, down 4.7%, and an annual FY2025 reading of $3.1 million, down 4.7% over the prior year.
  • Capital Leases was $3.1 million for Q4 2025 at SAB Biotherapeutics, down from $3.2 million in the prior quarter.
  • Across five years, Capital Leases topped out at $3.8 million in Q4 2021 and bottomed at $3.1 million in Q4 2025.
  • Average Capital Leases over 5 years is $3.4 million, with a median of $3.4 million recorded in 2023.
  • The sharpest move saw Capital Leases fell 3.53% in 2022, then decreased 5.9% in 2024.
  • Year by year, Capital Leases stood at $3.8 million in 2021, then decreased by 3.53% to $3.6 million in 2022, then decreased by 5.82% to $3.4 million in 2023, then dropped by 4.17% to $3.3 million in 2024, then decreased by 4.7% to $3.1 million in 2025.
  • Business Quant data shows Capital Leases for SABS at $3.1 million in Q4 2025, $3.2 million in Q3 2025, and $3.2 million in Q2 2025.